Continuation phase intravenous ketamine in adults with treatment-resistant depression

Jennifer Vande Voort, Robert J. Morgan, Simon Kung, Keith G. Rasmussen, Jose Rico, Brian A. Palmer, Kathryn M. Schak, Susannah J Tye, Matthew J. Ritter, Mark A Frye, William V Bobo

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background Little is known about the antidepressive effects of repeated intravenous ketamine infusions beyond the acute phase of treatment in patients with refractory depression. Methods Twelve subjects with treatment-resistant non-psychotic unipolar or bipolar major depression and suicidal ideation were given repeated (up to 6) thrice-weekly acute-phase intravenous infusions of ketamine (0.5 mg/kg, administered over 100 min). Those who remitted during acute-phase treatment received continuation-phase treatment that consisted of 4 weekly ketamine infusions, followed by 4 weeks of post-continuation phase follow-up (during which no further ketamine infusions were administered). Clinical measures were assessed at baseline, at 24 h following each infusion, at the last acute-phase observation, and during continuation and post-continuation follow-up (acute phase remitters only). Results Of the 12 enrollees, 5 (41.7%) remitted and 7 (58.3%) responded to ketamine treatment during the acute-phase. All five subjects who remitted during the acute-phase experienced further depressive symptom improvement during continuation-phase treatment. Four subjects lost remission status during the post-continuation phase, but all were still classified as positive treatment responders at the end of the post-continuation phase. Adverse effects were generally mild and transient during acute- and continuation-phase treatment; however, one subject developed behavioral outbursts and suicide threats during follow-up while hospitalized, and one subject died by suicide several weeks after the end of follow-up. Limitations This was an uncontrolled feasibility study with a small sample size. Conclusions The continuation-phase administration of ketamine at weekly intervals to patients with treatment-resistant depression who remitted during acute-phase ketamine treatment can extend the duration of depressive symptom remission. The antidepressive effect of ketamine persisted for several weeks after the end of continuation-phase treatment. Our results highlight the need for close monitoring of subjects who are at high baseline risk for suicide but do not respond clinically to ketamine. ClinicalTrials.gov identifier NCT02094898.

Original languageEnglish (US)
Pages (from-to)300-304
Number of pages5
JournalJournal of Affective Disorders
Volume206
DOIs
StatePublished - Dec 1 2016

Fingerprint

Treatment-Resistant Depressive Disorder
Ketamine
Suicide
Therapeutics
Intravenous Infusions
Depression
Suicidal Ideation
Feasibility Studies
Bipolar Disorder
Sample Size
Observation

Keywords

  • Bipolar depression
  • Continuation
  • Depression
  • Ketamine
  • Major depression
  • Repeated
  • Treatment resistant

ASJC Scopus subject areas

  • Medicine(all)
  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Continuation phase intravenous ketamine in adults with treatment-resistant depression. / Vande Voort, Jennifer; Morgan, Robert J.; Kung, Simon; Rasmussen, Keith G.; Rico, Jose; Palmer, Brian A.; Schak, Kathryn M.; Tye, Susannah J; Ritter, Matthew J.; Frye, Mark A; Bobo, William V.

In: Journal of Affective Disorders, Vol. 206, 01.12.2016, p. 300-304.

Research output: Contribution to journalArticle

Vande Voort, Jennifer ; Morgan, Robert J. ; Kung, Simon ; Rasmussen, Keith G. ; Rico, Jose ; Palmer, Brian A. ; Schak, Kathryn M. ; Tye, Susannah J ; Ritter, Matthew J. ; Frye, Mark A ; Bobo, William V. / Continuation phase intravenous ketamine in adults with treatment-resistant depression. In: Journal of Affective Disorders. 2016 ; Vol. 206. pp. 300-304.
@article{b893cb9836ef4a9d874aaa81455aae51,
title = "Continuation phase intravenous ketamine in adults with treatment-resistant depression",
abstract = "Background Little is known about the antidepressive effects of repeated intravenous ketamine infusions beyond the acute phase of treatment in patients with refractory depression. Methods Twelve subjects with treatment-resistant non-psychotic unipolar or bipolar major depression and suicidal ideation were given repeated (up to 6) thrice-weekly acute-phase intravenous infusions of ketamine (0.5 mg/kg, administered over 100 min). Those who remitted during acute-phase treatment received continuation-phase treatment that consisted of 4 weekly ketamine infusions, followed by 4 weeks of post-continuation phase follow-up (during which no further ketamine infusions were administered). Clinical measures were assessed at baseline, at 24 h following each infusion, at the last acute-phase observation, and during continuation and post-continuation follow-up (acute phase remitters only). Results Of the 12 enrollees, 5 (41.7{\%}) remitted and 7 (58.3{\%}) responded to ketamine treatment during the acute-phase. All five subjects who remitted during the acute-phase experienced further depressive symptom improvement during continuation-phase treatment. Four subjects lost remission status during the post-continuation phase, but all were still classified as positive treatment responders at the end of the post-continuation phase. Adverse effects were generally mild and transient during acute- and continuation-phase treatment; however, one subject developed behavioral outbursts and suicide threats during follow-up while hospitalized, and one subject died by suicide several weeks after the end of follow-up. Limitations This was an uncontrolled feasibility study with a small sample size. Conclusions The continuation-phase administration of ketamine at weekly intervals to patients with treatment-resistant depression who remitted during acute-phase ketamine treatment can extend the duration of depressive symptom remission. The antidepressive effect of ketamine persisted for several weeks after the end of continuation-phase treatment. Our results highlight the need for close monitoring of subjects who are at high baseline risk for suicide but do not respond clinically to ketamine. ClinicalTrials.gov identifier NCT02094898.",
keywords = "Bipolar depression, Continuation, Depression, Ketamine, Major depression, Repeated, Treatment resistant",
author = "{Vande Voort}, Jennifer and Morgan, {Robert J.} and Simon Kung and Rasmussen, {Keith G.} and Jose Rico and Palmer, {Brian A.} and Schak, {Kathryn M.} and Tye, {Susannah J} and Ritter, {Matthew J.} and Frye, {Mark A} and Bobo, {William V}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.jad.2016.09.008",
language = "English (US)",
volume = "206",
pages = "300--304",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

TY - JOUR

T1 - Continuation phase intravenous ketamine in adults with treatment-resistant depression

AU - Vande Voort, Jennifer

AU - Morgan, Robert J.

AU - Kung, Simon

AU - Rasmussen, Keith G.

AU - Rico, Jose

AU - Palmer, Brian A.

AU - Schak, Kathryn M.

AU - Tye, Susannah J

AU - Ritter, Matthew J.

AU - Frye, Mark A

AU - Bobo, William V

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background Little is known about the antidepressive effects of repeated intravenous ketamine infusions beyond the acute phase of treatment in patients with refractory depression. Methods Twelve subjects with treatment-resistant non-psychotic unipolar or bipolar major depression and suicidal ideation were given repeated (up to 6) thrice-weekly acute-phase intravenous infusions of ketamine (0.5 mg/kg, administered over 100 min). Those who remitted during acute-phase treatment received continuation-phase treatment that consisted of 4 weekly ketamine infusions, followed by 4 weeks of post-continuation phase follow-up (during which no further ketamine infusions were administered). Clinical measures were assessed at baseline, at 24 h following each infusion, at the last acute-phase observation, and during continuation and post-continuation follow-up (acute phase remitters only). Results Of the 12 enrollees, 5 (41.7%) remitted and 7 (58.3%) responded to ketamine treatment during the acute-phase. All five subjects who remitted during the acute-phase experienced further depressive symptom improvement during continuation-phase treatment. Four subjects lost remission status during the post-continuation phase, but all were still classified as positive treatment responders at the end of the post-continuation phase. Adverse effects were generally mild and transient during acute- and continuation-phase treatment; however, one subject developed behavioral outbursts and suicide threats during follow-up while hospitalized, and one subject died by suicide several weeks after the end of follow-up. Limitations This was an uncontrolled feasibility study with a small sample size. Conclusions The continuation-phase administration of ketamine at weekly intervals to patients with treatment-resistant depression who remitted during acute-phase ketamine treatment can extend the duration of depressive symptom remission. The antidepressive effect of ketamine persisted for several weeks after the end of continuation-phase treatment. Our results highlight the need for close monitoring of subjects who are at high baseline risk for suicide but do not respond clinically to ketamine. ClinicalTrials.gov identifier NCT02094898.

AB - Background Little is known about the antidepressive effects of repeated intravenous ketamine infusions beyond the acute phase of treatment in patients with refractory depression. Methods Twelve subjects with treatment-resistant non-psychotic unipolar or bipolar major depression and suicidal ideation were given repeated (up to 6) thrice-weekly acute-phase intravenous infusions of ketamine (0.5 mg/kg, administered over 100 min). Those who remitted during acute-phase treatment received continuation-phase treatment that consisted of 4 weekly ketamine infusions, followed by 4 weeks of post-continuation phase follow-up (during which no further ketamine infusions were administered). Clinical measures were assessed at baseline, at 24 h following each infusion, at the last acute-phase observation, and during continuation and post-continuation follow-up (acute phase remitters only). Results Of the 12 enrollees, 5 (41.7%) remitted and 7 (58.3%) responded to ketamine treatment during the acute-phase. All five subjects who remitted during the acute-phase experienced further depressive symptom improvement during continuation-phase treatment. Four subjects lost remission status during the post-continuation phase, but all were still classified as positive treatment responders at the end of the post-continuation phase. Adverse effects were generally mild and transient during acute- and continuation-phase treatment; however, one subject developed behavioral outbursts and suicide threats during follow-up while hospitalized, and one subject died by suicide several weeks after the end of follow-up. Limitations This was an uncontrolled feasibility study with a small sample size. Conclusions The continuation-phase administration of ketamine at weekly intervals to patients with treatment-resistant depression who remitted during acute-phase ketamine treatment can extend the duration of depressive symptom remission. The antidepressive effect of ketamine persisted for several weeks after the end of continuation-phase treatment. Our results highlight the need for close monitoring of subjects who are at high baseline risk for suicide but do not respond clinically to ketamine. ClinicalTrials.gov identifier NCT02094898.

KW - Bipolar depression

KW - Continuation

KW - Depression

KW - Ketamine

KW - Major depression

KW - Repeated

KW - Treatment resistant

UR - http://www.scopus.com/inward/record.url?scp=84987940053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987940053&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2016.09.008

DO - 10.1016/j.jad.2016.09.008

M3 - Article

C2 - 27656788

AN - SCOPUS:84987940053

VL - 206

SP - 300

EP - 304

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -